search
Back to results

A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

Primary Purpose

Primary Hypertension

Status
Active
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)
Original antihypertensive treatment (compulsively randomized arm)
Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)
Original antihypertensive treatment (voluntarily randomized arm)
Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)
Original antihypertensive treatment (preference selection arm)
Sponsored by
Jiangxi University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosed with essential hypertension, i.e., systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg, with a course more than 6 months.
  2. Ages: 18-80 years;
  3. The original antihypertensive drugs are calcium channel blockers and/or angiotensin II receptor blockers.
  4. Did not receive acupoint stimulation therapies for hypertension in the last month.
  5. Patients in the heat-sensitive moxibustion groups need to develop at least one type of moxibustion sensation around the following acupoints: Yongquan, Baihui, Shenque, Quchi, Zusanli, Hegu, Taichong and Dazhui.
  6. Consent to sign an informed consent form

Exclusion Criteria:

  1. Systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg after taking antihypertensive drugs;
  2. Secondary hypertension.
  3. Pregnancy and lactation;
  4. Allergic to moxibustion devices, moxa smoke or Artemisia argyi.
  5. Complicated with severe diseases that are not recommended for heat-sensitive moxibustion, such as acute cerebral hemorrhage, hypertensive crisis, sensory disturbances, serious mental diseases, etc.

Sites / Locations

  • Erliuling
  • Hongmiao
  • Jinghexinggong community
  • Jinsheng community
  • Nangang community
  • Shajing
  • Wuliangdian community

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

Heat-sensitive moxibustion group A

Control group A

Heat-sensitive moxibustion group B

Control group B

Heat-sensitive moxibustion group C

Control group C

Arm Description

In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Outcomes

Primary Outcome Measures

Systolic blood pressure
Changes from baseline in systolic blood pressure

Secondary Outcome Measures

Diastolic blood pressure
Changes from baseline in diastolic blood pressure
Response to treatment
Definition: (i) a decrease in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg; or (ii) blood pressure control of < 140 mmHg systolic and < 90 mmHg diastolic in patients aged ≥ 65 years; blood pressure control of < 130 mmHg systolic and < 80 mmHg diastolic in patients aged < 65 years.
Dose of antihypertensive drugs
Changes from baseline in dose of antihypertensive drugs
Score of EQ-5D-5L
Quality of life will be measured using Euro-Qol-5 Dimensions-5 Levels questionnaire (EQ-5D-5L)
Symptom score
Symptoms will be scored using the scale in "Guiding Principles of Clinical Research on New Drugs of Chinese Medicines"
Cost-effectiveness ratio
Outpatient and inpatient costs for each group will be recorded and used to calculate the cost-effectiveness ratio
Patients' compliance to heat-sensitive moxibustion
Patients' compliance will be assessed by recording the frequency and duration of heat-sensitive moxibustion.
Incidence of cardiovascular events
Newly developed cardiovascular events
Any adverse events
Adverse event data will be derived from patient self-reports and physician reviews.
Heat-sensitive moxibustion-related adverse events
Heat-sensitive moxibustion-related adverse event data will be derived from patient self-reports and physician reviews.

Full Information

First Posted
March 5, 2021
Last Updated
January 17, 2022
Sponsor
Jiangxi University of Traditional Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04788563
Brief Title
A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community
Official Title
Heat-sensitive Moxibustion Self-administration for Primary Hypertension in Community: A Multicenter, Pragmatic, Randomized Controlled Trial With Patient Preference Arms
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 10, 2021 (Actual)
Primary Completion Date
June 30, 2022 (Anticipated)
Study Completion Date
June 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jiangxi University of Traditional Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Heat-sensitive moxibustion, an important mean of external therapy of traditional Chinese medicine, has unique advantages in treating various chronic diseases than common moxibustion. This study aims to evaluate the efficacy, safety, and cost-effectiveness of heat-sensitive moxibustion for primary hypertension under community self-management setting using a multicenter, pragmatic, randomized controlled trial design with patient-preference arms.
Detailed Description
Primary hypertension is a common chronic disease that threatens the life and health of human beings. The conventional western drug therapy often has side effects and many patients are unable to achieve ideal blood pressure control with drugs alone. Therefore, the treatment of primary hypertension still requires active exploration of complementary and alternative therapies with clear clinical efficacy. Heat-sensitive moxibustion is an innovative moxibustion therapy. By stimulating the patient's special moxibustion sensation, heat-sensitive moxibustion can achieve better results than traditional moxibustion for many diseases, including primary hypertension. Heat-sensitive moxibustion is an easy, inexpensive and safe treatment method. The practitioner does not need to be professionally qualified to perform moxibustion, making it a suitable technique for patients to self-medicate on a daily basis. Traditional moxibustion has been shown to lower blood pressure in patients with primary hypertension. Theoretically, heat-sensitive moxibustion could achieve better blood pressure lowering effects, but its effects in lowering blood pressure in the setting of self-management in community patients is unclear. To verify the efficacy and safety of heat-sensitive moxibustion community self-management for hypertension, we plan to perform a randomized controlled trial. In this trial, we designed the trial grouping scheme as a randomized controlled trial with patient preference arms in order to improve patient adherence and reduce the impact of patient preference effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial with patient preference arms
Masking
Outcomes Assessor
Masking Description
Data analysts will be blinded.
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Heat-sensitive moxibustion group A
Arm Type
Experimental
Arm Description
In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Arm Title
Control group A
Arm Type
Active Comparator
Arm Description
In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Arm Title
Heat-sensitive moxibustion group B
Arm Type
Experimental
Arm Description
Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Arm Title
Control group B
Arm Type
Active Comparator
Arm Description
Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Arm Title
Heat-sensitive moxibustion group C
Arm Type
Experimental
Arm Description
Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Arm Title
Control group C
Arm Type
Active Comparator
Arm Description
Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).
Intervention Type
Other
Intervention Name(s)
Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)
Intervention Description
In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
Intervention Type
Drug
Intervention Name(s)
Original antihypertensive treatment (compulsively randomized arm)
Intervention Description
In this group, patients will maintain their original antihypertensive treatment.
Intervention Type
Other
Intervention Name(s)
Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)
Intervention Description
In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
Intervention Type
Drug
Intervention Name(s)
Original antihypertensive treatment (voluntarily randomized arm)
Intervention Description
In this group, patients will maintain their original antihypertensive treatment.
Intervention Type
Other
Intervention Name(s)
Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)
Intervention Description
In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
Intervention Type
Drug
Intervention Name(s)
Original antihypertensive treatment (preference selection arm)
Intervention Description
In this group, patients will maintain their original antihypertensive treatment.
Primary Outcome Measure Information:
Title
Systolic blood pressure
Description
Changes from baseline in systolic blood pressure
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Secondary Outcome Measure Information:
Title
Diastolic blood pressure
Description
Changes from baseline in diastolic blood pressure
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Response to treatment
Description
Definition: (i) a decrease in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg; or (ii) blood pressure control of < 140 mmHg systolic and < 90 mmHg diastolic in patients aged ≥ 65 years; blood pressure control of < 130 mmHg systolic and < 80 mmHg diastolic in patients aged < 65 years.
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Dose of antihypertensive drugs
Description
Changes from baseline in dose of antihypertensive drugs
Time Frame
Measure at baseline screening, monthly for 6 months
Title
Score of EQ-5D-5L
Description
Quality of life will be measured using Euro-Qol-5 Dimensions-5 Levels questionnaire (EQ-5D-5L)
Time Frame
Baseline and months 3 and 6
Title
Symptom score
Description
Symptoms will be scored using the scale in "Guiding Principles of Clinical Research on New Drugs of Chinese Medicines"
Time Frame
Baseline and months 3 and 6
Title
Cost-effectiveness ratio
Description
Outpatient and inpatient costs for each group will be recorded and used to calculate the cost-effectiveness ratio
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Patients' compliance to heat-sensitive moxibustion
Description
Patients' compliance will be assessed by recording the frequency and duration of heat-sensitive moxibustion.
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Incidence of cardiovascular events
Description
Newly developed cardiovascular events
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Any adverse events
Description
Adverse event data will be derived from patient self-reports and physician reviews.
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6
Title
Heat-sensitive moxibustion-related adverse events
Description
Heat-sensitive moxibustion-related adverse event data will be derived from patient self-reports and physician reviews.
Time Frame
Baseline and months 1, 2, 3, 4, 5, and 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with essential hypertension, i.e., systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg, with a course more than 6 months. Ages: 18-80 years; The original antihypertensive drugs are calcium channel blockers and/or angiotensin II receptor blockers. Did not receive acupoint stimulation therapies for hypertension in the last month. Patients in the heat-sensitive moxibustion groups need to develop at least one type of moxibustion sensation around the following acupoints: Yongquan, Baihui, Shenque, Quchi, Zusanli, Hegu, Taichong and Dazhui. Consent to sign an informed consent form Exclusion Criteria: Systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg after taking antihypertensive drugs; Secondary hypertension. Pregnancy and lactation; Allergic to moxibustion devices, moxa smoke or Artemisia argyi. Complicated with severe diseases that are not recommended for heat-sensitive moxibustion, such as acute cerebral hemorrhage, hypertensive crisis, sensory disturbances, serious mental diseases, etc.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xu Zhou, M.D.
Organizational Affiliation
Jiangxi University of Traditional Chinese Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Erliuling
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Hongmiao
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Jinghexinggong community
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Jinsheng community
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Nangang community
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Shajing
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China
Facility Name
Wuliangdian community
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330004
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35172871
Citation
Zhou X, Li S, Li L, Deng G, Dai L, Chai L, Wu Q, Yao Z, Deng M, Zhu W, Fu Y, Sun X. Community-based heat-sensitive moxibustion for primary hypertension: study protocol for a randomized controlled trial with patient-preference arms. Trials. 2022 Feb 16;23(1):154. doi: 10.1186/s13063-022-06092-4.
Results Reference
derived

Learn more about this trial

A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

We'll reach out to this number within 24 hrs